Antimicrobial Prophylaxis in Prostate Surgery
Conditions
Keywords
Greenlight Laser Vaporisation of the Prostate, Transurethral resection of the prostate, Cotrimoxazole Prophylaxis
Brief summary
The optimal duration of antimicrobial prophylaxis (study medication Cotrimoxazole (Trimethoprim/Sulfamethoxazole)) in transurethral resection of the prostate and Greenlight Laser vaporisation of the prostate is investigated by comparing a guideline-conform single-dose prophylaxis (intervention) versus usual clinical care (i.e. 3-day prophylaxis; control) for prevention of urinary tract infections.
Detailed description
Increasing antimicrobial resistance rates have a substantial impact on morbidity, mortality and healthcare costs and is particularly prevalent among urological patients due to an overuse of antimicrobial agents for therapeutical and prophylactic indications. Transurethral resection of the prostate is one of the most frequently performed urological procedures in Switzerland and a single-dose of antimicrobial prophylaxis is recommended to reduce postoperative urinary tract infections. For photoselective vaporisation of the prostate with the Greenlight Laser, a similar operative alternative, there are currently no international guidelines for antimicrobial prophylaxis. The optimal duration of antimicrobial prophylaxis in transurethral resection of the prostate and Greenlight Laser vaporisation of the prostate is investigated by comparing a guideline-conform single-dose prophylaxis (intervention) versus usual clinical care (i.e. 3-day prophylaxis; control) for prevention of urinary tract infections. The study medication Cotrimoxazole (Trimethoprim/Sulfamethoxazole) is a routinely used antimicrobial substance recommended in international and in-house guidelines for antimicrobial prophylaxis and treatment of urinary tract infections. Perioperative antimicrobial prophylaxis will be Cotrimoxazole short infusion in both groups. Postoperative study medication packages consists of either five tablets of placebo or five tablets of Cotrimoxazole (Nopil forte®) 800/160mg using licensed product repacked in a new immediate container which is blinded
Interventions
DRUGoral applications of TMP/SMX 800/160 mg (Nopil forte® tablets)
five oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets) at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
DRUGoral applications of Placebo
five oral applications of Placebo at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
Sponsors
Swiss National Science Foundation
University Hospital, Basel, Switzerland
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Intervention model description
single-dose application of Cotrimoxazole compared to a 3-day application of Cotrimoxazole
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Obstructive voiding disorder (e.g. benign prostate hyperplasia, obstructive prostate cancer) * Planned Transurethral resection of the prostate (TURP) or Greenlight Laser (GL)
Exclusion criteria
* Evidence for (catheter associated-) UTI, with or without antibiotic treatment in the last 7 days prior to randomisation. * Any evidence of a history of positive urine culture (cfu ³105/ml in midstream-urine with no more than two species) and resistance to TMP/SMX in the last 7 days prior to randomisation. * Known contraindication against study drugs according to the Swissmedic package leaflet (e.g. known liver dysfunction, renal insufficiency; patients with glomerular filtration rate (calculated by the Modification of Diet in Renal Disease (MDRD) or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) \<30ml/min or dialysis patients will be excluded). * Antibiotic treatment for any reason within 7 days prior to randomisation * Indication for Antibiotic prophylaxis (AP) for other reasons (e.g. endocarditis prophylaxis, transplanted patients under systemic immunosuppression).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Symptomatic UrinaryTract Infection (UTI) | within 30 days after randomization | Symptomatic UTI (based on clinical diagnosis) treated with antimicrobial agents |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Symptomatic cystitis (based on clinical diagnosis) | within 30 days after randomization | Symptomatic cystitis (based on clinical diagnosis) |
| Symptomatic epididymitis (based on clinical diagnosis) | within 30 days after randomization | Symptomatic epididymitis (based on clinical diagnosis) |
| Symptomatic pyelonephritis (based on clinical diagnosis) | within 30 days after randomization | Symptomatic pyelonephritis (based on clinical diagnosis) |
| Symptomatic prostatitis (based on clinical diagnosis) | within 30 days after randomization | Symptomatic prostatitis (based on clinical diagnosis) |
| Symptomatic urethritis (based on clinical diagnosis) | within 30 days after randomization | Symptomatic urethritis (based on clinical diagnosis) |
| Urosepsis (based on clinical diagnosis) | within 30 days after randomization | Urosepsis (based on clinical diagnosis) |
| Prescription of antibiotics (for any reason) | within 30 days after randomization | Prescription of antibiotics (for any reason) |
| Prescribed defined daily doses (DDD) of antibiotics (cumulative sum of DDD) day 30) | within 30 days after randomization | Prescribed defined daily doses (DDD) of antibiotics (cumulative sum of DDD) |
| Asymptomatic bacteriuria of ≥105 cfu/ml treated with antimicrobial agents | within 30 days after randomization | Asymptomatic bacteriuria of ≥105 cfu/ml treated with antimicrobial agents |
| Detection of multidrug-resistant bacteria in Urine culture | within 30 days after randomization | Detection of multidrug-resistant bacteria in Urine culture |
| Symptomatic UTI by measured bacteriuria | within 30 days after randomization | measured bacteriuria of ≥105 cfu/ml treated with antimicrobial agents (key secondary outcome) |
| Duration of catheterisation (cumulative sum of days between randomisation and end of catheterisation or day 30) | within 30 days after randomization | Duration of catheterisation (cumulative sum of days between randomisation and end of catheterisation or day 30) |
| Duration of hospital stay (cumulative sum of Hospital days between randomisation and day 30) | within 30 days after randomization | Duration of hospital stay (cumulative sum of Hospital days between randomisation and day 30) |
| Duration of intensive care unit (ICU) stay (cumulative sum of ICU days between randomisation and day 30) | within 30 days after randomization | Duration of intensive care unit stay (cumulative sum of ICU days between randomisation and day 30) |
| Re-hospitalisation (within 30 days after randomisation) | within 30 days after randomization | Re-hospitalisation (within 30 days after randomisation) |
| Change of International Prostate Symptom Score (prior to randomisation and at day 30 after randomisation) | within 30 days after randomization | Change of International Prostate Symptom Score (prior to randomisation and at day 30 after randomisation) |
| Change of Quality of life Score (prior to randomisation and at day 30 after randomisation) | within 30 days after randomization | Change of Quality of life Score (prior to randomisation and at day 30 after randomisation) |
| All-cause mortality | within 30 days after randomization | All-cause mortality |
| Total adverse events | within 30 days after randomization | Total adverse events |
| Total serious adverse events | within 30 days after randomization | Total serious adverse events |
| Any Clostridium difficile-associated infection | within 30 days after randomization | Any Clostridium difficile-associated infection |
Countries
Switzerland
Outcome results
None listed